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Angiogenesis is critical for tumor growth
and is a complex process involving
matrix breakdown, endothelial sprouting
from preexisting vessels, endothelial
proliferation, migration, differentiation to
form tubes, and recruitment of peri-
cytes/smooth muscle cells (SMCs).
Interactions between tumor cells,
endothelial cells (ECs), and stromal cells
are crucial for tumor angiogenesis.
Various angiogenic molecules produced
by either tumor cells or tumor stromal
cells can directly bind to their cognate
receptors on ECs and thus initiate angio-
genesis. For instance, vascular endothe-
lial growth factor (VEGF) secreted by
tumor cells and fibroblast growth factor
(FGF) generated by tumor fibroblasts are
classical proangiogenic factors. Thus, a
paracrine regulation of angiogenesis by
secreted proteins is a well-recognized
mechanism.
The Notch signaling pathway is an
evolutionarily conserved intercellular sig-
naling mechanism, affecting many differ-
entiation processes and cell-fate
determination during embryonic and
postnatal development. Four Notch
receptors (Notch1–Notch4) and five DSL
(named for Delta and Serrate from
Drosophila and Lag-2 from C. elegans)
ligands (Jagged1, Jagged2, delta-like1
[DLL1], DLL3, and DLL4) have been
described in mammals. Activation of
Notch signaling is mediated by interac-
tions of bordering cells via cell-to-cell
contact of the membrane-associated
Notch receptor and ligand (Figure 1).
The Notch pathway is involved in
multiple aspects of vascular develop-
ment and angiogenesis. Major compo-
nents of the Notch pathway existing in
vasculature consist of three receptors
(Notch1, -3, and -4), three ligands
(DLL4, Jagged1, and Jagged2), and
three downstream targets (Hey1, -2,
and -L). Mice deficient for a variety of
these components, including Notch1,
Notch1/Notch4, Jagged1, DLL1, DLL4,
Hey1/Hey2, and presenilins (PS1 and
PS2) resulted in embryonic lethality
with vascular remodeling defects (for
review, see Iso et al., 2003). In human,
mutations in the Jagged1 and Notch3
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Notch signaling is an evolutionarily conserved pathway and plays key roles in embryonic vascular development and angio-
genesis. Multiple components of the Notch pathway are expressed in vasculature, and mice deficient for a variety of these
components display embryonic lethality with vascular remodeling defects. Alteration of Notch signaling in various
endothelial cells generates profound effects on angiogenesis in vitro. New evidence shows that Notch signaling from
tumor cells is able to activate endothelial cells and trigger tumor angiogenesis in vitro and in a xenograft mouse tumor
model. Selective interruption of Notch signaling within tumors may provide an antiangiogenic strategy.
Figure 1. Crosstalk between tumor cells, endothelial cells, and stromal cells is modulated by the Notch pathway and stimulates tumor 
angiogenesis
The tumor-associated growth factors HGF, EGF, and TGFα, produced by tumor cells and/or stromal cells, induce Jagged1 expression in tumor cells
(probably in endothelial cells as well) through MAPK pathway. Jagged1 on tumor cells binds to Notch receptor(s) on endothelial cells. Upon ligand
binding, the Notch intracellular domain (NICD) is released from the endothelial cell plasma membrane by the γ-secretase-dependent proteolytic
cleavages of Notch receptor. The NICD then
translocates to the nucleus, where it interacts
with the CSL (named for mammalian
CBF1/RBP-Jκ, Drosophila Su(H), and C. 
elegans Lag-1) transcription repressor to 
activate the transcription of target genes. 
The basic-helix-loop-helix proteins (bHLH)
Hairy/Enhancer of Split (Hes1, -5, and -7) and
Hes-related proteins (Hey1, -2, and -L) are the
best-characterized downstream targets. The
Notch signaling from the tumor cells is able to
activate endothelial cells and thus initiate
tumor angiogenesis. Accordingly, the neovas-
culature is able to stimulate the tumor growth
and progression. The γ-secretase inhibitor IX (γ-
SI IX) and soluble Jagged1 (sJag1) can pro-
tect the proteolytic cleavage by inhibiting the
γ-secretase activity and block the interaction
of Jagged1 and Notch, respectively, and
therefore prevent the endothelial activation.
Notch cross-signaling between tumor cells,
stromal cells, and endothelial cells is likely to
regulate the interaction of Notch ligands on
tumor cells with receptors on endothelial cells,
and vice versa. Tumor-associated stromal
fibroblasts and inflammation stimulate tumor
angiogenesis and tumor growth and progres-
sion. VEGF secreted by tumor cells and FGF
generated by tumor fibroblasts promote
tumor angiogenesis.
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genes cause the autosomal dominant
disorders Alagille syndrome and
CADASIL, respectively, and both dis-
play abnormal vascular phenotypes.
Haploinsufficiency of DLL4 also result-
ed in embryonic lethality from severe
vascular defects in mice (Gale et al.,
2004). The only other angiogenic path-
way for which haploinsufficiency is
reported is for VEGF knockout mice.
Remarkably, EC-specific knockin of
Notch4 active form and knockout of
either Notch1 or Notch1/Notch4 pro-
duced similar phenotypes (Uyttendaele
et al., 2001), suggesting that either
excessive upregulation or downregula-
tion is detrimental to vascular develop-
ment, and thus, a narrow range of
optimal expression seems to be 
essential.
The role of the Notch signaling in
angiogenesis has been evaluated by
manipulating the expression of different
components in ECs. Overexpression of
Hey1 in human capillary ECs blocked
angiogenesis in vitro; however, reduction
of Hey1 expression by antisense oligonu-
cleotides also blocked the endothelial
network formation. Constitutive activation
of Notch signaling by expressing N1ICD
or Hes1 inhibited human iliac artery EC
(HIAEC) proliferation but increased the
endothelial survival and network forma-
tion on matrigel and vessel-like cord for-
mation in a 3D collagen angiogenesis
model, whereas blocking Notch signaling
by expressing a dominant-negative form
of CSL decreased the network and cord
formation in the 3D model (Liu et 
al., 2003). However, overexpression of
N4ICD or CSL in human dermal
microvascular EC (HMEC-1) inhibited the
endothelial migration and sprouting in
vitro and angiogenesis in the chick
chorioallantoic membrane in vivo (Leong
et al., 2002). Activation of the Notch path-
way by Jagged1, N1ICD, and N4ICD
inhibited proliferation of human umbilical
vein ECs (HUVECs) and human aortic
ECs (HAECs) (Noseda et al., 2004),
while Jagged1 was able to induce
microvessel-like structures in vitro.
Overexpression of the dominant-negative
form of Jagged1 (sJag1) in HUVEC inhib-
ited the endothelial network formation.
However, addition of an antisense
Jagged1 oligonucleotide to bovine
microvascular ECs (BMECs) enhanced
the FGF-dependent invasion and tube
formation of BMECs. Thus, although
Notch has critical roles in vivo in the
embryonic vascular development, in vitro
it appears that function of the Notch path-
way in ECs is dependent on the endothe-
lial type, and activation of Notch signaling
is likely to inhibit endothelial proliferation.
However, information about Notch
signaling in tumor angiogenesis is limit-
ed. It is known that DLL4 is upregulated
in the vasculature of human xenografted
tumors in mice, and in human breast
cancers and kidney cancers (Mailhos et
al., 2001), and DLL4 reporter seems to
be preferentially induced in the vascula-
ture of mouse Lewis lung carcinoma
(Gale et al., 2004). Recently, it has been
demonstrated that DLL4 expression is
upregulated about 9-fold in clear cell
renal cell carcinoma and is correlated
with VEGF expression. Reduction of
basal DLL4 level in ECs by siRNA led to
the inhibition of multiple endothelial func-
tions in vitro including proliferation,
migration, and network formation, imply-
ing the potential role of this pathway in
cancer (Patel et al., 2005).
Wang and colleagues now provide
new information that Notch signaling
from tumor cells can trigger the Notch
activation of neighboring ECs and con-
sequently promote tumor angiogenesis
(Zeng et al., 2005, this issue of Cancer
Cell) (Figure 1). These authors demon-
strate that Jagged1 is expressed in head
and neck squamous cell carcinoma
(HNSCC) cells and is induced through
MAPK pathway by HGF, EGF, and TGFα,
all of which, together with their receptors,
are associated with HNSCC develop-
ment and progression. Cocultivation 
of human dermal microvascular ECs
(HDMECs) with HGF-treated or Jagged1-
transformed SCC9 tumor cells
(SCC9/Jag1) was able to activate Notch
signaling in HDMECs and stimulate the
endothelial network formation on
matrigel. Coimplantation of HDMEC and
SCC9/Jag1 in SCID mice showed that
Jagged1-transformed tumor cells pro-
moted tumor angiogenesis and tumor
growth. Investigation of 102 cases of
patient tumor tissues demonstrated that
the level of Jagged1 expression was
positively correlated with blood vessel
density and associated with HNSCC
development. Thus, this study showed
the juxtacrine effects of tumor cells on
endothelium, which may also be impor-
tant if tumor cells contribute directly to
vessel walls with endothelial cells.
However, there are several issues
worthy of further consideration. Wang
and colleagues have shown that overex-
pression of N1ICD in HDMEC is able to
promote endothelial network formation.
Given that all four Notch receptors are
expressed in ECs (Patel et al., 2005), we
wonder if other Notches are also involved
in the binding of Jagged1 on SSC tumor
cells. Jagged1 is also expressed in ECs
(Figure 1). Thus, whether the Jagged1
signaling from tumor cells affects
endothelial Jagged1 function or differs
from endothelial Jagged1 signaling
needs to be addressed. It will be interest-
ing to investigate which downstream tar-
gets in ECs are responsible for the
function. From the above evidence, Notch
signaling is likely to involve differentiation
rather than proliferation, and thus interac-
tions with angiopoietins will need to be
examined. Moreover, tumor-associated
stromal fibroblasts and inflammation
stimulate tumor angiogenesis and growth
(Sparmann and Bar-Sagi, 2004; Orimo et
al., 2005). Therefore, Notch cross-signal-
ing between tumors cells, stromal cells,
and ECs is likely to regulate the interac-
tion of Notch ligands on tumor cells with
receptors on ECs.
Nevertheless, the findings of Wang
and colleagues highlight that tumor cells
express Notch ligands that are able to
stimulate tumor angiogenesis and tumor
growth. Specific interruption of the
Jagged1 signaling within human tumors
may provide a potential novel antiangio-
genic therapy. Interaction with conven-
tional pathways may be important.VEGF
and bFGF were able to induce the
expression of DLL4, Notch1, and Notch4
in HUVEC (Liu et al., 2003; Patel et al.,
2005), and Notch1, Notch4, and Hey1
can downregulate VEGFR2 expression.
The latter observation raises possible
risks for Notch inhibition, in that VEGFR2
signaling may go up. Therefore, a com-
bined approach, e.g., interruption of
Notch signaling combined with VEGF
inhibitors, may be required.
Ji-Liang Li1,* and Adrian L. Harris1,*
1Cancer Research UK Molecular 
Oncology Laboratories
Weatherall Institute of Molecular Medicine
John Radcliffe Hospital
University of Oxford
Oxford OX3 9DS, United Kingdom
*E-mail: lij@cancer.org.uk; 
aharris.lab@cancer.org.uk
Selected reading
Gale, N.W., Dominguez, M.G., Noguera, I., Pan,
L., Hughes, V., Valenzuela, D.M., Murphy, A.J.,
P R E V I E W S
CANCER CELL : JULY 2005 3
Adams, N.C., Lin, H.C., Holash, J., et al. (2004).
Proc. Natl. Acad. Sci. USA 101, 15949–15954.
Iso, T., Hamamori, Y., and Kedes, L. (2003).
Arterioscler. Thromb. Vasc. Biol. 23, 543–553.
Leong, K.G., Hu, X., Li, L., Noseda, M., Larrivee,
B., Hull, C., Hood, L., Wong, F., and Karsan, A.
(2002). Mol. Cell. Biol. 22, 2830–2841.
Liu, Z.J., Shirakawa, T., Li, Y., Soma, A., Oka, M.,
Dotto, G.P., Fairman, R.M., Velazquez, O.C., and
Herlyn, M. (2003). Mol. Cell. Biol. 23, 14–25.
Mailhos, C., Modlich, U., Lewis, J., Harris, A.,
Bicknell, R., and Ish-Horowicz, D. (2001).
Differentiation 69, 135–144.
Noseda, M., Chang, L., McLean, G., Grim, J.E.,
Clurman, B.E., Smith, L.L., and Karsan, A.
(2004). Mol. Cell. Biol. 24, 8813–8822.
Orimo, A., Gupta, P.B., Sgroi, D.C., Arenzana-
Seisdedos, F., Delaunay, T., Naeem, R., Carey,
V.J., Richardson, A.L., and Weinberg, R.A.
(2005). Cell 121, 335–348.
Patel, N.S., Li, J.L., Generali, D., Cranston, D.W.,
and Harris, A.L. (2005). Cancer Res. 65, in press.
Sparmann, A., and Bar-Sagi, D. (2004). Cancer
Cell 6, 447–458.
Uyttendaele, H., Ho, J., Rossant, J., and
Kitajewski, J. (2001). Proc. Natl. Acad. Sci. USA
98, 5643–5648.
Zeng, Q., Li, S., Chepeha, D.B., Giordano, T.J.,
Li, J., Zhang, H., Polverini, P.J., Nor, J.,
Kitajewski, J., and Wang, C.-Y. (2005). Cancer
Cell 8, this issue.
DOI: 10.1016/j.ccr.2005.06.013
P R E V I E W S
Persistent proliferation and enhanced
cell survival are hallmarks of aggressive
tumor cells. Two key proteins that sup-
press abnormal cell proliferation are the
RB and p53 tumor suppressors. RB acts
as a brake to block cell cycle progression
through its ability to repress E2F, a tran-
scription factor that activates genes
essential for the S phase of the cell cycle
(for review, see Sherr, 2004). p53 also
blocks cell proliferation in part by induc-
ing p21CIP1, a protein that binds and
inhibits the cyclin/CDK complexes, which
are required for progression through the
cell cycle. Additionally, p53 induces cell
death by activating the expression of
genes involved in apoptosis (for review,
see Vogelstein et al., 2000). Therefore,
not surprisingly, most cancer cells have
inactivated both of these factors either
directly or indirectly to sever their signal-
ing pathways.
Recently, Fujita and colleagues
(Higashitsuji et al., 2000) identified
gankyrin as a gene that was consistently
overexpressed in human liver cancers.
Gankyrin is highly conserved throughout
evolution (?40% identity to yeast Nas6P)
(Hori et al. 1998) and is localized on
human chromosome Xq22.3 in a region
where DNA gains are frequently detected
in kidney and colon carcinomas. Whether
gankyrin expression is deregulated in
cancers other than liver tumors is not yet
known. Gankyrin contains two special
domains consisting of ankyrin repeats
and the RB-recognition motif LxCxE
(178LACDE182), and derives its name from
these features. “Gann” is the Japanese
word for cancer, and ankyrin is the func-
tional domain involved in protein-protein
interactions.
Gankyrin was initially purified and
characterized by Tanaka and coworkers
(Hori et al., 1998) as the p28 component
of the regulatory subunit of the 26S pro-
teasome, which is an ATP-dependent
protease responsible for the degradation
of proteins.The observation that gankyrin
binds RB, but not p107 or p130 (RB relat-
ed proteins), in vitro and in vivo when
ectopically expressed provided an initial
glimpse into the role of gankyrin in
tumorigenesis (Higashitsuji et al., 2000).
Consistent with these findings, enforced
expression of gankyrin in immortalized
mouse fibroblasts and human tumor cells
conferred growth in soft agar, and this
transformation phenotype was depen-
dent on the ability of gankyrin to bind RB
(e.g., the LxCxE point mutant E182A is
inactive). Interestingly, a splice variant of
gankyrin is produced that lacks the
LACDE motif, which should render it
inactive in targeting RB directly. However,
the physiologic role of this variant and
how gankyrin gene expression is regulat-
ed in general has not yet been explored.
Gankyrin facilitates the phosphorylation
and degradation of RB (Figure 1), sug-
gesting that increased expression of
gankyrin promotes tumorigenicity by tar-
geting RB to the proteasome. Yet
gankyrin disrupts RB function by other
means as well. Gankyrin also binds
cyclin-dependent kinase 4 (CDK4) result-
ing in a gankyrin-CDK4-Cyclin D ternary
complex (Li and Tsai, 2002). In so doing,
gankyrin competes with INK4A, an
inhibitor of cyclin kinases, for binding to
CDK4. Based upon these findings,
gankyrin appears to indirectly activate
CDK4, resulting in the hyperphosphory-
lation of RB and concomitant deregula-
tion of E2F1-mediated transcription and
cell cycle progression (Figure 1). Taken
together, these studies suggest that
gankyrin deactivates the RB tumor sup-
pressor pathway at multiple levels,
including by direct binding to RB and by
ensuring its inactivation through the
maintenance of CDK4 kinase activity.
In the present study in Cancer Cell
by Fujita and colleagues (Higashitsuji et
al., 2005), gankyrin is now shown to bind
to MDM2, an E3 ubiquitin ligase that
negatively regulates p53. Compelling
data are provided showing that this inter-
action occurs naturally between endoge-
Gankyrin: An intriguing name for a novel regulator of p53 and RB
The RB and p53 tumor suppressors lie at the heart of cancer biology, and inactivation of both pathways is seemingly
essential for tumor development. Previous studies identified gankyrin as a component of the 26S proteasome that is con-
sistently overexpressed in liver cancer and promotes cell transformation by binding RB. In the current issue of Cancer Cell,
Fujita and colleagues (Higashitsuji et al., 2005) show that gankyrin also binds MDM2 and facilitates its destruction of p53.
These important findings implicate gankyrin as a dual-purpose negative regulator of RB and p53, thereby identifying
gankyrin as a rational cancer therapeutic target.
